Cacna1c CRISPRa kit - CRISPR gene activation of mouse calcium channel, voltage-dependent, L type, alpha 1C subunit
| Format | 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug) |
Products
qSTAR qPCR primer pairs against Mus musculus gene Cacna1c
qSTAR qPCR primer pairs against Homo sapiens gene CACNA1C
Goat Anti-CACNA1C Antibody
| Applications | WB |
| Reactivities | Human |
Cacna1c (Mouse) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Cacna1c (untagged ORF) - Rat calcium channel, voltage-dependent, L type, alpha 1C subunit (Cacna1c), (10 ug)
| Type | Rat Untagged Clone |
| Tag | Tag Free |
| Vector | pCMV6-Entry |
Cacna1c - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
Transient overexpression of CACNA1C, transcript variant 18, in HEK293T cells, FFPE control for IHC, ICC and ISH staining, 25 slides per pack
Cacna1c - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
CACNA1C - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Cacna1c - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Rabbit Polyclonal Anti-CACNA1C Antibody
| Applications | IHC |
| Reactivities | Human |
活动过滤器
优化搜索结果
Species
Reactivities
Antibody Hosts
Expression Hosts
Lentivirus
Vectors
Reporters
Conjugates
Clonalities
Mutants
Assay Types
Pathways
- Alzheimer's disease (81)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (81)
- Calcium signaling pathway (81)
- Cardiac muscle contraction (81)
- Dilated cardiomyopathy (81)
- GnRH signaling pathway (81)
- Hypertrophic cardiomyopathy (HCM) (81)
- Long-term potentiation (81)
- MAPK signaling pathway (81)
- Type II diabetes mellitus (81)
- Vascular smooth muscle contraction (81)
